The problem is Argenbarx is that the age has got it wrong, why...

The problem is Argenbarx is that the age has got it wrong, why don't they look at what Calzada released recently about AQOD9604, it was their own subsidiary Metabolic Pharmaceuticals that developed the drug in the first place and it was Metabolic Pharma that trialled the drug in the fist place, they proved it was not harmful to Humans along with many other facts about the compound.

26 April 2013
AOD9604
–
Important Clarifications
Metabolic Pharmaceuticals Pty Ltd (a wholly owned subsidiary of Calzada Ltd (ASX:CZD)
)
is concerned by a number of factual errors and misrepresentations in relation to its AOD9604 compound
in the current public discussion on the drugs in sport issue.
The following information is provided in order to correct and clarify some of those statements and references.

What is AOD9604?
AOD9604 is a small peptide compound modeled o
n the fat metabolizing region of human growth hormone
(hGH).
The make-up of AOD9604 represents only a small
fragment of human growth hormone (hGH).
It is not hGH and it is not a variant of hGH.
It consists of less than 8% of the homology of hGH. There
exists substantial scientific and medical evidence showing that AOD9604 has none of the safety concerns associated
with hGH.

AOD9604 development thus far
AOD9604 was initially targeted as a potential treatment for obesity.
Metabolic Pharmaceuticals has previously conducted six human clinical studies involving 925 patients. While the trials proved that AOD9604 was profoundly safe, they did not
show a clinically meaningful weight loss outcome across the total trial population.

As a result the obesity program was terminated in February 2007.

Over the last 2 years, Metabolic Pharmaceuticals has found that AOD9604 may have potential to be used as a
treatment for the repair of cartilage, muscle and joint disorders such as Osteoarthritis.

To date,work has only been done in preclinical studies.
It appears that only a repair function is triggered by AOD9604 by providing the progenitors or ingredients required to enable a repair to occur.

Results from past in-vitro , pre-clinical and human clinical testing of AOD9604 provide clear scientific and
medical evidence that AOD9604 does not increase Insulin-like
Growth Factor 1 (IGF-1) levels.

Furthermore,there is no evidence that AOD9604 dosing increases the number of muscle or cartilage cells.

The “Black Market”use of AOD9604 During calendar 2010 Calzada released two statements to the Australian
Securities
Exchange regarding “black market” sales of AOD9604.
The announcements stated that AOD9604 was being manufactured in China and elsewhere and sold into various countries around the world - in direct contravention of the Company’s patent position.

Sales were primarily to distributors, gymnasiums, weight control centres, private clinics and individuals
(athletes, bodybuilders and the obese)

Metabolic Pharmaceuticals were the people who developed the drug and trialled it , they are now part of Calzada, but Calzada have NEVER supplied AOD9604 to anyone except for the trials they did, all of the information that was supplied with the Black Market drug AOD9604 has NEVER been tested clinically, it is just snake oil salesmen who tend to make incorrect claims as to what AOD9604 can do, myy only concern is that what was purchased as AOPD9604 on the black market is purely AOD9604 and not something that also contained steroid type substances as well, because these substabnces obtained illegally on the black market hyave NEVER been tested in the clinic as far as I know?

http://www.asx.com.au/asxpdf/20130426/pdf/42fh15rvm7p65t.pdf